Interventions in progressive supranuclear palsy

Christos Koros; Maria Stamelou

doi:10.1016/j.parkreldis.2015.09.033

Interventions in progressive supranuclear palsy

Parkinsonism Relat Disord. 2016 Jan:22 Suppl 1:S93-5. doi: 10.1016/j.parkreldis.2015.09.033. Epub 2015 Sep 25.

Authors

Christos Koros¹, Maria Stamelou²

Affiliations

¹ Movement Disorders Clinic, Second Dept. of Neurology, Attikon Hospital, University of Athens, Greece.
² Movement Disorders Clinic, Second Dept. of Neurology, Attikon Hospital, University of Athens, Greece; Dept. of Movement Disorders, Hygeia Hospital, Athens, Greece; Neurology Clinic, Philipps University, Marburg, Germany. Electronic address: mariastamelou@gmail.com.

PMID: 26459661
DOI: 10.1016/j.parkreldis.2015.09.033

Abstract

Progressive supranuclear palsy (PSP) an atypical parkinsonian with a common phenotype comprising early falls, the characteristic slowing of vertical saccades and a frontal syndrome with marked apathy (Richardson's syndrome). Currently, no effective symptomatic or neuroprotective treatment is available for PSP. Current medical have a limited role in PSP. Novel experimental treatments include davunetide or tideglusib, both inhibitors of glycogen synthase kinase-3 (GSK-3) that failed to improve the clinical outcome of PSP patients in two recent studies. Future interventions aiming at tau dysfunction and passive or active immunization are ongoing or underway.

Keywords: Davunetide; Glycogen synthase kinase-3 inhibitors; Immunization; Progressive supranuclear palsy; Richardson's syndrome; Tideglusib; Treatment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Brain / drug effects
Brain / pathology
Clinical Trials as Topic / methods
Glycogen Synthase Kinase 3 / antagonists & inhibitors*
Humans
Supranuclear Palsy, Progressive / diagnosis*
Supranuclear Palsy, Progressive / drug therapy*
Thiadiazoles / pharmacology
Thiadiazoles / therapeutic use

Substances

Thiadiazoles
Glycogen Synthase Kinase 3
tideglusib